Aura Biosciences, Inc.
AURA
$7.00
$0.142.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 29.33% | -6.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.01% | -2.40% | |||
| Operating Income | -28.01% | 2.40% | |||
| Income Before Tax | -31.83% | 2.15% | |||
| Income Tax Expenses | -26.67% | -42.31% | |||
| Earnings from Continuing Operations | -31.79% | 2.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.79% | 2.19% | |||
| EBIT | -28.01% | 2.40% | |||
| EBITDA | -28.28% | 2.39% | |||
| EPS Basic | -31.11% | 3.89% | |||
| Normalized Basic EPS | -31.15% | 3.84% | |||
| EPS Diluted | -31.11% | 3.89% | |||
| Normalized Diluted EPS | -31.15% | 3.84% | |||
| Average Basic Shares Outstanding | 0.52% | 1.76% | |||
| Average Diluted Shares Outstanding | 0.52% | 1.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||